Avid Bioservices Inc (CDMO)

[cjgaddy]

Peregrine Presenting 4-8-14 at BIO Asia Intl. Conf. in Tokyo

April 8-9 2014: “11th Annual BIO Asia Intl. Conf.”, Tokyo
http://www.bio.org/events/conferences/11th-annual-bio-asia-international-conference
”The BIO Asia Intl. Conf.is an exclusive, customized partnering forum that brings together U.S. & European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements. The conference features private, pre-arranged meetings between senior-level executives… The format & selective nature of the conference makes this the premier dedicated biotech partnering event in Asia and an unrivalled opportunity to meet with the leading international pharmaceutical and biotech companies in one place at one time.”
Presenting Companies (23 a/o 3-25-14): http://www.bio.org/node/23267
• Peregrine Pharmaceuticals - Tuesday, 4-8-14 3:30pm, Sage Room

= = = = = = =AS VG Reminds us:
H. 1st Investigator-Sponsored (IST) Ph.I/II Trial (Bavi+Sorafenib vs. Liver Cancer/HCC, open-label)
...Note: Sorafenib = Onyx/Bayer's Nexavar - see http://www.nexavar.com
Protocol: http://clinicaltrials.gov/ct2/show/NCT01264705 UTSW: http://tinyurl.com/mwdc2ql (5 sites: 3/UTSW, Parkland-Hosp, Dallas/VA)
...4-4-12 AACR'12: Dr. Adam Yopp, "promising safety profile to-date" http://tinyurl.com/7yrwqm7 (see #5591)
...Feb'12-Mar'13 ~8 times: CEO Steve King hints of future ex-US partner-driven Bavi+Sorafenib/LIVER trial in Asia: http://tinyurl.com/la5t9cq
......Articles & Data describe Liver Cancer challenges in Asian populations: http://tinyurl.com/7z7o8j9 & http://tinyurl.com/7z99cy4
...12-1-10: PPHM's 1st IST (Liver Cancer) initiated at UTSW, ~56 patients - http://tinyurl.com/3xd3e6c
…Per S.King, 5-18-10/R&R, "We've had a lot of interest in running clinical trials with the compound from investigators who have either had prior experience with the drug or would like to study the drug in various settings. Potential IST indications include all the major solid tumor types. Of particular interest is Liver Cancer, in which we have a natural tie-in with our HCV program, Ovarian Cancer and Pancreatic Cancer, also very nicely supported by the prior data."